Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma.

A genome-wide allelic analysis of neuroblastoma (NB) revealed a previously undescribed increased incidence of loss of heterozygosity (LOH) on chromosome arm 19q13 primarily affecting stages 3 and 4N disease. Further allelic analysis of chromosome 19q13 in a cohort of 116 NB patients using 17 polymorphic microsatellite markers identified the shortest common region of loss between D19S606 and D19S112 at 19q13.3. In some cases, clonal LOH at 19q13 was acquired during the course of disease, and deleted clones remained after cytotoxic therapy. In multivariant analysis, 19q13 LOH was associated with overall survival in local-regional International Neuroblastoma Staging System stages 1, 2, and 3 patients and was specifically present in tumors at the site of recurrence.

[1]  W. Gerald,et al.  Laser-capture microdissected schwannian and neuroblastic cells in stage 4 neuroblastomas have the same genetic alterations. , 2000, Medical and pediatric oncology.

[2]  B. Scheithauer,et al.  Mapping of the chromosome 19 q‐arm glioma tumor suppressor gene using fluorescence in situ hybridization and novel microsatellite markers , 2000, Genes, chromosomes & cancer.

[3]  M. LaQuaglia,et al.  Local control with multimodality therapy for stage 4 neuroblastoma. , 2000, International journal of radiation oncology, biology, physics.

[4]  D. Louis,et al.  A transcript map of the chromosome 19q-arm glioma tumor suppressor region. , 2000, Genomics.

[5]  W. Gerald,et al.  Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. , 2000, The Journal of molecular diagnostics : JMD.

[6]  D. Louis,et al.  The human glia maturation factor-gamma gene: genomic structure and mutation analysis in gliomas with chromosome 19q loss , 1999, Neurogenetics.

[7]  B. Scheithauer,et al.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.

[8]  K K Matthay,et al.  Molecular biology of neuroblastoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Ault,et al.  Loss of heterozygosity in human ovarian cancer on chromosome 19q. , 1997, Gynecologic oncology.

[10]  David N. Louis,et al.  ANOVA, a putative astrocytic RNA-binding protein gene that maps to chromosome 19q13.3 , 1997, Neurogenetics.

[11]  D. Louis,et al.  The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. , 1996, Cancer genetics and cytogenetics.

[12]  W. Gerald,et al.  Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  D. Louis,et al.  Chromosome 19q Deletions in Human Gliomas Overlap Telomeric to D19S219 and May Target a 425 kb Region Centromeric to D19S112 , 1995, Journal of neuropathology and experimental neurology.

[14]  J. Rey,et al.  Allelic loss at 1p and 19q frequently occurs in association and may represent early oncogenic events in oligodendroglial tumors , 1995, International journal of cancer.

[15]  W. Gerald,et al.  Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[17]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[18]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[19]  D. Cox.  Regression Models and Life-Tables , 1972 .